Mycophenolic Acid

Mycophenolic Acid

SCHEMBL1230249

COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2.[NaH]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

IMPDH1IMPDH2

The experimentally established mechanism targets of Mycophenolic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 known ✓ P12268 20/20 1.00
IMPDH1 known ✓ P20839 10/20 1.00
KDM4E B2RXH2 1/20 1.00
ALDH1A1 P00352 1/20 1.00
LMNA P02545 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
HPGD P15428 1/20 1.00
UGT2B7 P16662 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HSD17B10 Q99714 1/20 1.00
HDAC3 O15379 2/20 0.79
HDAC4 P56524 2/20 0.79
HDAC1 Q13547 2/20 0.79
HDAC7 Q8WUI4 2/20 0.79
HDAC2 Q92769 2/20 0.79
HDAC10 Q969S8 2/20 0.79
HDAC11 Q96DB2 2/20 0.79
HDAC8 Q9BY41 2/20 0.79
HDAC6 Q9UBN7 2/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mycophenolic Acid SCHEMBL1657813 1.00 IMPDH2 (1.00) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL29645054 1.00 IMPDH2 (1.00) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL2514376 1.00 IMPDH2 (1.00) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL29380425 1.00 IMPDH2 (1.00) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL4549 1.00 IMPDH2 (1.00) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL5259872 1.00 IMPDH2 (1.00) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL5500098 1.00 IMPDH2 (1.00) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL6502425 0.99 IMPDH2 (0.98) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL3652377 0.99 IMPDH2 (0.98) IMPDH2IMPDH1KDM4EALDH1A1LMNA
Mycophenolic Acid SCHEMBL1657815 0.99 IMPDH2 (0.98) IMPDH2IMPDH1KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11987804-B2 Rapamycin resistant cells SEATTLE CHILDREN'S HOSPITAL (US) 2024-05-21 US claimed
US-20240117008-A1 METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN ENGINEERED CELLS IN VITRO AND IN VIVO Seattle Children's Hospital (dba Seattle Children's Research Institute) 2024-04-11 US claimed
US-20230416361-A1 ENGINEERED CD200R ANTIBODIES AND USES THEREOF OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-12-28 US claimed
EP-4267171-A1 ARTIFICIAL ANTIGEN-SPECIFIC IMMUNOREGULATORY T (AIRT) CELLS Seattle Children's Hospital (DBA Seattle Children's Research Institute) (US) 2023-11-01 EP claimed
WO-2023196866-A1 ENGINEERED CD200R ANTIBODIES AND USES THEREOF MIROBIO LIMITED (GB) 2023-10-12 WO claimed
WO-2022140354-A1 ARTIFICIAL ANTIGEN-SPECIFIC IMMUNOREGULATORY T (AIRT) CELLS Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2022-06-30 WO claimed
US-20210228629-A1 ANTI-BCMA CAR-T-CELLS FOR PLASMA CELL DEPLETION BAYER HEALTHCARE LLC 2021-07-29 US claimed
US-20210069249-A1 METHODS AND COMPOSITIONS OF CYTOTOXIC T CELL DEPLETION BAYER HEALTHCARE LLC 2021-03-11 US claimed
EP-3784694-A1 METHODS AND COMPOSITIONS OF CYTOTOXIC T CELL DEPLETION CRISPR Therapeutics AG (CH) 2021-03-03 EP claimed
EP-3784259-A1 RAPAMYCIN RESISTANT CELLS Seattle Children's Hospital (DBA Seattle Children's Research Institute) (US) 2021-03-03 EP claimed
US-20050203612-A1 Luminal prostheses which allow for programmed and controlled delivery of mycophenolic acid or derivatives with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis and hyperplasia AVANTEC VASCULAR CORPORATION (US) 2005-09-15 US claimed
EP-1539041-A1 DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME Avantec Vascular Corporation (US) 2005-06-15 EP claimed
WO-2005051229-A2 DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME AVANTEC VASCULAR CORPORATION (US) 2005-06-09 WO claimed
US-20050125054-A1 Devices delivering therapeutic agents and methods regarding the same AVANTEC VASCULAR CORPORATION (US) 2005-06-09 US claimed
EP-1536839-A2 METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON Intarcia Therapeutics, Inc. (US) 2005-06-08 EP claimed
WO-2004010900-A1 DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME AVANTEC VASCULAR CORPORATION (US) 2004-02-05 WO claimed
WO-2003063573-A2 METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON INTARCIA THERAPEUTICS, INC. (US) 2003-08-07 WO claimed
US-20030143197-A1 Method for treating diseases with omega interferon INTARCIA THERAPEUTICS, INC. 2003-07-31 US claimed
US-20030050692-A1 Delivery of therapeutic capable agents AVANTEC VASCULAR CORPORATION 2003-03-13 US claimed
WO-2003009777-A2 DELIVERY OF THERAPEUTIC CAPABLE AGENTS AVANTEC VASCULAR CORPORATION (US) 2003-02-06 WO claimed